Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT00466531 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: therapeutic autologous lymphocytes
DRUG: cyclophosphamide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]